Ketamine Dosing Strategy for Rapid PTSD Symptom Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for post-traumatic stress disorder (PTSD) are challenging, with limited efficacy from selective serotonin reuptake inhibitors (SSRIs) and a need for novel pharmacological interventions targeting the core pathophysiology of PTSD, particularly in combat veterans.
Innovation Solution
The use of ketamine, administered in sub-anesthetic doses ranging from 0.01 to 2.0 mg/kg, either intravenously or intranasally, as a glutamatergic NMDA receptor antagonist to treat PTSD, potentially combined with adjunctive therapies like antidepressants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If SSRIs are used as first-line pharmacotherapy for PTSD, then treatment coverage is provided, but efficacy is limited with up to 40% of patients not responding and >70% never achieving full remission
Solution Approach 1:
The patent changes the pharmacological parameter from SSRIs (serotonin reuptake inhibition) to ketamine (NMDA receptor antagonism), representing a fundamental shift in the mechanism of action. This parameter change enables the treatment to target different neurobiological pathways involved in PTSD, thereby improving efficacy in patients who do not respond to SSRIs.
Solution Approach 2:
Ketamine demonstrates multi-functionality by addressing multiple symptom clusters of PTSD (re-experiencing, avoidance and numbing, andhyperarousal) simultaneously through a single mechanism of NMDA receptor antagonism. This universal approach improves adaptability across diverse patient populations and symptom presentations.
2Power
If high doses of ketamine are administered to achieve anesthetic properties, then potent pharmacological effect is achieved, but side effects increase and safety concerns arise
Solution Approach 1:
The patent applies local quality by administering ketamine at different dose levels for different therapeutic purposes: subanesthetic doses (0.01-2.0 mg/kg) for PTSD treatment with minimal side effects, versus higher anesthetic doses for surgical anesthesia. This localized dosing strategy optimizes therapeutic effect while minimizing harmful effects.
Solution Approach 2:
The patent uses partial action by administering subanesthetic doses of ketamine that are sufficient to achieve NMDA receptor antagonism and PTSD symptom relief, but insufficient to produce full anesthetic effects. This partial dosing approach achieves the necessary therapeutic effect while avoiding excessive pharmacological action and associated side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Ketamine demonstrates rapid and significant alleviation of PTSD symptoms, including flashbacks, emotional numbness, and insomnia, with minimal side effects, offering a novel approach to treating this debilitating disorder.
Implementation Method 1
Ketamine is an antagonist of NMDA-type glutamate receptors
Data Source
AI summary
The present disclosure provides compositions containing ketamine and methods of using those compositions for the treatment of post-traumatic stress disorder.